Panelists discuss how familial chylomicronemia syndrome (FCS) is diagnosed and managed, emphasizing the role of early intervention in preventing severe complications and exploring current and emerging RNA interference–based therapies, such as APOC3 and ANGPTL3 inhibitors, which offer new avenues for effective triglyceride control and potential improvements in patient outcomes.
Panelists discuss how familial chylomicronemia syndrome (FCS) is characterized by severe hypertriglyceridemia and genetic mutations in the LPL gene, highlighting the key diagnostic criteria and complications, such as acute pancreatitis, while emphasizing the impact of untreated FCS on patient quality of life and long-term health risks.
Panelists discuss how familial chylomicronemia syndrome (FCS) imposes a significant economic burden on patients, affecting their ability to stay employed and manage the costs associated with long-term care and treatment.
Panelists discuss how a multidisciplinary approach enhances the management of familial chylomicronemia syndrome by fostering collaboration among clinicians to address unmet treatment needs and optimize patient outcomes, while also exploring existing treatment gaps that contribute to ongoing risks of acute pancreatitis and hospitalization.
Panelists discuss how early diagnosis and intervention in familial chylomicronemia syndrome (FCS) are crucial for preventing cardiovascular and metabolic complications, emphasizing the key role clinicians play in initiating timely and effective treatment strategies.
Panelists discuss how various new and developing approaches for treating familial chylomicronemia syndrome are emerging, and emphasize the importance for clinicians to integrate these advancements into practice while staying current with ongoing research and evolving treatment strategies.
Panelists discuss how the SHASTA-2 study evaluated the efficacy and safety of plozasiran in reducing triglyceride levels and APOC3 in familial chylomicronemia syndrome, comparing outcomes with the placebo group and assessing implications for treating severe hypertriglyceridemia and preventing pancreatitis.
Panelists discuss how various new and developing approaches for treating familial chylomicronemia syndrome are emerging, and emphasize the importance for clinicians to integrate these advancements into practice while staying current with ongoing research and evolving treatment strategies.
